Document:

Exhibit
10.1

 

MariMed
Inc.

 

SECOND
AMENDMENT TO EMPLOYMENT AGREEMENT

Effective
Date: May 12, 2022

 

This
Second Amendment to the Employment Agreement (this “Agreement”) is between MARIMED INC., a Delaware corporation (the “Company”
or “MariMed”), and JON R. LEVINE, an individual (the “Executive”).

 

WHEREAS,
the Company and the Executive entered into an Employment Agreement effective as of dated July 1, 2021, as amended by the First Amendment
to Employment Agreement effective as of September 22, 2021, providing for the continued employment of the Executive as its Chief Financial
Officer (the “Original Agreement”); and

 

WHEREAS,
the Company and the Executive seeks to amend the Original Agreement in accordance with the terms of this Agreement.

 

NOW,
THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereto agree as follows:

 

1. The
Original Agreement is hereby amended as follows:

 

(a)
Section 2(a) of the Original Agreement is hereby amended to change Executive’s title, duties and responsibilities and as amended
Section 2(a) shall read as follows:

 

“During
the Term, the Executive will serve as the Chief Administrative Officer of the Company. The Executive will have such duties and responsibilities
as are customary for the position of Chief Administrative Officer including oversight of the Company’s strategic growth plan and
day-to-day operations, and supervision and oversight of the Company’s finance, sales, marketing and human relations function, and
such other duties and responsibilities as are reasonably assigned to him by the Board of Directors of the Company (the “Board”).
The Executive shall report to and be supervised by the Board.”; and

 

(b)
All references to “Chief Financial Officer” are hereby amended and replaced with “Chief Administrative Officer.”

 

2. Except
as otherwise amended by this Agreement, all other provisions of the Agreement shall remain in full force and effect.

 

[SIGNATURE
PAGE FOLLOWS ON THE NEXT PAGE]

 

    	 

     

    

 

The
undersigned hereby execute this Agreement as of the Effective Date stated above.

 

	MARIMED INC.	 
	 	 	 
	By:	 	 
	 	Robert Fireman	 
	 	Chief Executive Officer	 
	 	 	 
	 	 	 
	 	Jon R. Levine	 

 

    	2Exhibit
10.2

 

MARIMED
INC.

 

Stock
Option Agreement

(this
“Agreement”)

 

Dated:
May 2, 2022

(“Grant
Date”)

 

MariMed
Inc., a Delaware corporation (the “Company”), in accordance with the Company’s Amended and Restated 2018 Stock
Award and Incentive Plan (the “Plan”) hereby grants to Susan Villare (the “Optionee”), a stock option
to purchase a total of 400,000 shares of the Company’s Common Stock, par value $.001 per share (the “Common Stock”),
at a price of $0.64 per share (the “Exercise Price”), on the terms and conditions set forth herein and in the Plan.

 

	 	1.	Term.

 

Subject
to Optionee’s continued employment with the Company on each such date, this option shall vest (the “Vesting Date”):

 

	 	●	With
    respect to 100,000 shares of Common Stock on the six (6) month anniversary of the Grant Date (the “Initial Vesting Date”);
    and
	 	●	For
    an additional 100,000 shares of Common Stock on the last day of every succeeding six (6) month period after the Initial Vesting Date.

 

This
option shall expire five (5) years from the date hereof (the “Termination Date”).

 

Notwithstanding
the foregoing, in the event of a “change in control” (as defined in the Plan), this option shall fully and automatically
vest in its entirety and be immediately exercisable to purchase all the shares of Common Stock granted pursuant to this Agreement.

 

	 	2.	Characterization
    of Options.

 

 The
option granted pursuant to this Agreement is intended to constitute and qualify as an Incentive Stock Option, as defined by §422
of the Internal Revenue Code of 1986, as amended (the “Code”). To the extent this option does not meet the criteria
of an Incentive Stock Option as defined in §422 of the Code it shall constitute a non-qualified stock option subject to §83
of the Code.  

 

	 	3.	Exercise
    of Options.

 

(a)  Subject to earlier termination or cancellation as provided in this Agreement, this option may
be exercised at any time on or after the Vesting Date hereof, in whole or in part, as follows and on or prior the Termination Date:

 

for
100% of the vested shares on or after the date hereof.

 

    	1

     

    

 

(b) To the extent vested prior to the Termination Date, this option shall be exercisable by written
notice of such exercise, in the form prescribed by the Board of Directors of the Company (the “Board”), to the Secretary
or Treasurer of the Company at its principal office. The notice shall specify the number of shares of Common Stock for which the option
is being exercised (which number, if less than all of the shares then subject to exercise, shall be 50 or a multiple thereof) and shall
be accompanied by payment (i) in cash or by check in the amount equal to the Exercise Price multiplied by the number of shares to be
purchased upon exercise, or (ii) in such other manner as the Board shall deem acceptable. No shares shall be delivered upon exercise
of any option until all laws, rules and regulations which the Board may deem applicable have been complied with.

 

(c) The Optionee shall not be considered a record holder of the Common Stock issuable pursuant
to this Agreement for any purpose until the date on which he or she is actually recorded as the holder of such Common Stock in the records
of the Company.

 

(d) To the extent vested, prior to the Termination Date, this option shall be exercisable only
so long as the Optionee shall continue to hold the same or similar position with the Company as is currently held by the Optionee, or
such other position as may have been directed by the Board and within the ninety (90) day period after the date of termination of such
relationship, to the extent vested on such date of termination; provided, however, such termination was without cause.

 

(e)
Notwithstanding the provision of Section 3(d) above:

 

(i)
In the event the Optionee is unable to continue to hold the same or similar position with the Company as is currently held by the Optionee,
or such other position as may have been directed by the Board, due to his or her total and permanent disability (as defined in §105(d)(4)
of the Code), this option may be exercised, to the extent vested on the date of such disability, but only within the ninety (90) day
period from the date of such disability;

 

(ii)
In the event of death of the Optionee, this option may be exercised, to the extent vested on the date of death, at any time within twelve
(12) months following such date of death by the Optionee’s estate or by a person who acquired the right to exercise this option
by bequest or inheritance; provided that at the time of his or her death the Optionee held the same or similar position with the Company
as is currently held by the Optionee, or such other position as may have been directed by the Board; and

 

(iii)
In the event the Optionee is terminated from the Company for cause, this option may be exercised, to the extent vested on the date of
such termination, within the thirty (30) day period after the date of such termination.

 

Notwithstanding
the provisions of this Section (e), in no event shall this option be exercisable after the Termination Date.

 

	 	4.	Anti-Dilution
    Provisions.

 

(a)  If there is any stock dividend, stock split, or combination of shares of Common Stock, the
number and amount of shares then subject to this option shall be proportionately and appropriately adjusted; no change shall be made
in the aggregate purchase price to be paid for all shares subject to this option, but the aggregate purchase price shall be allocated
among all shares subject to this option after giving effect to the adjustment.

 

    	2

     

    

 

(b) If there is any other change in the Common Stock, including recapitalization, reorganization,
sale or exchange of assets, exchange of shares, offering of subscription rights, or a merger or consolidation in which the Company is
the surviving corporation, an adjustment, if any, shall be made in the shares then subject to this option as the Board may deem equitable.
Failure of the Board to provide for an adjustment pursuant to this subparagraph prior to the effective date of any Company action referred
to herein shall be conclusive evidence that no adjustment is required in consequence of such action.

 

(c) If the Company is merged into or consolidated with any other corporation, or if it sells all
or substantially all of its assets to any other corporation, then either (i) the Company shall cause provisions to be made for the continuance
of this option after such event, or for the substitution for this option of an option covering the number and class of securities which
the Optionee would have been entitled to receive in such merger or consolidation by virtue of such sale if the Optionee had been the
holder of record of a number of shares of Common Stock equal to the number of shares covered by the unexercised portion of this option,
or (ii) the Company shall give to the Optionee written notice of its election not to cause such provision to be made and this option
shall become exercisable in full (or, at the election of the Optionee, in part) at any time during a period of 20 days, to be designated
by the Company, ending not more than 10 days prior to the effective date of the merger, consolidation or sale, in which case this option
shall not be exercisable to any extent after the expiration of such 20-day period.

 

	 	5.	Investment
    Representation; Legend on Certificates; Special Restriction Resale.

 

The
Optionee agrees that until such time as a registration statement under the Securities Act of 1933, as amended (the “1933 Act”),
becomes effective with respect to the option and/or the stock, the Optionee is taking this option and will take the stock underlying
this option, for his or her own account, for investment and not with a view to the resale or distribution thereof. The Company shall
have the right to place upon the face of any stock certificate or certificates evidencing shares issuable upon the exercise of this option
such legend as the Board may prescribe for the purpose of preventing disposition of such shares in violation of the 1933 Act, as now
or hereafter provided.

 

	 	6.	Non-Transferability.

 

This
option shall not be transferable by the Optionee other than by will or by the laws of descent or distribution and is exercisable during
the lifetime of the Optionee only by the Optionee.

 

	 	7.	Certain
    Rights Not Conferred by Option.

 

The
Optionee shall not, by virtue of holding this option, be entitled to any rights of a stockholder in the Company.

 

	 	8.	Expenses.

 

The
Company shall pay all original issue and transfer taxes with respect to the issuance and transfer of shares of Common Stock pursuant
hereto and all other fees and expenses necessarily incurred by the Company in connection therewith.

 

	 	9.	Miscellaneous.

 

In
no event shall this option be exercisable after the Termination Date. Nothing herein shall be deemed to create any employment agreement
or guaranty of the Optionee’s position with the Company or limit in any way the Company’s right to terminate Optionee’s
position at any time.

 

    	3

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first above written.

 

	 	 	MARIMED
    INC.
	 	 	 	 
	 	 	By:	 
	 	 	 	Jon
    R. Levine, CFO
	 	 	 	 
	OPTIONEE:	 	 
	 	 	 	 
	 	 	 	 
	Name:	Susan
    Villare	 	 

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]